Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Consulting agrmnt
|
|
Rezolute, Inc. (RZLT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 06/02/2023 |
8-K
| Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhib... |
| 05/11/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
8-K
| Quarterly results |
| 01/13/2023 |
8-K
| Quarterly results |
| 12/15/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 09/15/2022 |
8-K
| Quarterly results |
| 07/01/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"UNDERWRITING AGREEMENT",
"FORM OF CLASS A PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK",
"FORM OF CLASS B PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK",
"FORM OF CLASS C PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK",
"Letter re: Registration Statement on Form S-3",
"FORM OF REGISTRATION RIGHTS AGREEMENT",
"PLACEMENT AGENCY AGREEMENT",
"SECURITIES PURCHASE AGREEMENT",
"FORM OF REGISTRATION RIGHTS AGREEMENT",
"Rezolute, Inc. Announces Closing of Registered Direct Offering REDWOOD CITY, Calif., May 4, 2022 -- Rezolute, Inc. , a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the closing of its previously announced underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 12,921,055 shares of common stock at an offering price of $3.799 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-fund..." |
|
| 05/02/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market REDWOOD CITY, Calif., May 1, 2022 -- Rezolute, Inc. , a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the pricing of an underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 12,921,055 shares of common stock at an offering price of $3.799 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.00...",
"Rezolute Announces Positive Data from its Phase 2b Study of RZ358 in Patients with Congenital Hyperinsulinism",
"Corporate Deck Restoring Balance to Life with Transformative Therapies April 2022 Forward Looking Statements Statements in" |
|
| 03/30/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/23/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/22/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/09/2022 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K
| Quarterly results|
Docs:
|
"Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress REDWOOD CITY, Calif., November 12, 2021 – Rezolute, Inc. , a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the first quarter of fiscal 2022 ended September 30, 2021. “This has been a productive quarter of execution for Rezolute, with steady clinical advancement of our lead pipeline candidates, RZ358 and RZ402, in Phase 2b and Phase 1b development, respectively,” said Nevan Elam, Chief Executive Officer and Founder of Rezolute. “We look forward to announcing topline data for both programs in Q1 of 2022. Additionally, with a strengthened balance sheet follo..." |
|
| 10/19/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 10/13/2021 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement, by and between the Company and Oppenheimer & Co., Inc",
"Form of Pre-Funded Warrant To Purchase Common Stock",
"Opinion of Dorsey & Whitney LLP",
"Form of Subscription Agreement",
"Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering REDWOOD CITY, Calif., October 12, 2021 – Rezolute, Inc. , a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, and, in lieu of common stock, Rezolute intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock. Concurrently with the public offering and by means of a prospectus supplement and accompanying prospectus, Rezolute is offering to sell shares of its common stock directly to certain institutional investors th...",
"Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering REDWOOD CITY, Calif., October 13, 2021 – Rezolute, Inc. , a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the pricing of an underwritten public offering of 6,030,847 shares of its common stock at a public offering price of $6.50 per share and of pre-funded warrants to purchase 1,661,461 shares of its common stock at a public offering price of $6.49 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each pre-funded warrant. In addition, Rezolute tod..." |
|
| 09/23/2021 |
8-K
| Quarterly results |
| 09/15/2021 |
8-K
| Quarterly results |
| 09/13/2021 |
8-K
| Quarterly results |
| 08/11/2021 |
8-K
| Quarterly results |
| 08/03/2021 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 06/28/2021 |
8-K
| Quarterly results |
| 06/02/2021 |
8-K
| Quarterly results |
| 05/17/2021 |
8-K
| Quarterly results |
| 05/04/2021 |
8-K
| Quarterly results |
| 04/19/2021 |
8-K
| Quarterly results |
| 03/08/2021 |
8-K
| Quarterly results |
| 02/18/2021 |
8-K
| Quarterly results |
| 02/10/2021 |
8-K
| Quarterly results |
|
|
|